Meag Munich Ergo’s AbbVie ABBV Stock Holding History

Meag Munich Ergo’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$30.2M	Sell	162,557 -13,715	-8%	-$2.55M	0.85%	48
2025 Q1	$36.9M	Buy	176,272 +925	+0.5%	+$180K	1.09%	46
2024 Q4	$30.9M	Buy	175,347 +2,781	+2%	+$511K	0.98%	51
2024 Q3	$34.1M	Buy	172,566 +3,902	+2%	+$728K	1.07%	42
2024 Q2	$28.9M	Buy	168,664 +77,785	+86%	+$12.9M	0.96%	46
2024 Q1	$16.5M	Sell	90,879 -3,878	-4%	-$668K	0.6%	51
2023 Q4	$14.7M	Buy	94,757 +1,720	+2%	+$251K	0.56%	59
2023 Q3	$13.9M	Buy	93,037 +191	+0.2%	+$28K	0.6%	56
2023 Q2	$12.5M	Sell	92,846 -619	-0.7%	-$90.8K	0.55%	61
2023 Q1	$14.9M	Buy	93,465 +43,055	+85%	+$6.58M	0.7%	51
2022 Q4	$8.15M	Sell	50,410 -254	-0.5%	-$38.9K	0.44%	51
2022 Q3	$6.8M	Buy	50,664 +311	+0.6%	+$44.6K	0.41%	51
2022 Q2	$7.71M	Buy	50,353 +49,853	+9,971%	+$7.62M	0.46%	46
2022 Q1	$82K	Sell	500 -2,954	-86%	-$429K	0.01%	194
2021 Q4	$471K	Hold	3,454	–	–	0.03%	139
2021 Q3	$373K	Hold	3,454	–	–	0.06%	158
2021 Q2	$389K	Sell	3,454 -66,923	-95%	-$7.54M	0.04%	283
2021 Q1	$7.62M	Buy	70,377 +50,634	+256%	+$5.42M	0.77%	27
2020 Q4	$2.08M	Sell	19,743 -6,843	-26%	-$658K	0.48%	62
2020 Q3	$2.33M	Sell	26,586 -16,383	-38%	-$1.54M	0.43%	60
2020 Q2	$4.22M	Hold	42,969	–	–	0.79%	27
2020 Q1	$3.27M	Sell	42,969 -34,635	-45%	-$2.95M	0.78%	31
2019 Q4	$6.87M	Sell	77,604 -66,494	-46%	-$5.52M	0.73%	31
2019 Q3	$10.7M	Buy	144,098 +53,070	+58%	+$3.64M	0.55%	42
2019 Q2	$6.38M	Buy	91,028 +6,870	+8%	+$540K	0.5%	47
2019 Q1	$6.72M	Buy	84,158 +76,308	+972%	+$6.24M	0.55%	43
2018 Q4	$708K	Sell	7,850 -122,256	-94%	-$10.8M	0.09%	265
2018 Q3	$12.2M	Sell	130,106 -22,780	-15%	-$2.16M	0.72%	30
2018 Q2	$14.3M	Sell	152,886 -53,066	-26%	-$5.18M	0.89%	23
2018 Q1	$19.3M	Sell	205,952 -34,190	-14%	-$3.76M	0.79%	23
2017 Q4	$23.6M	Buy	240,142 +100,287	+72%	+$9.45M	0.91%	18
2017 Q3	$12.5M	Sell	139,855 -151,347	-52%	-$11.5M	0.51%	57
2017 Q2	$21.1M	Sell	291,202 -13,153	-4%	-$884K	0.93%	21
2017 Q1	$19.9M	Buy	304,355 +193,856	+175%	+$12.2M	0.79%	24
2016 Q4	$6.97M	Sell	110,499 -403,238	-78%	-$24.6M	0.32%	110
2016 Q3	$32.3M	Buy	513,737 +89,271	+21%	+$5.78M	1.59%	9
2016 Q2	$26M	Buy	424,466 +173,542	+69%	+$10.6M	2.36%	3
2016 Q1	$14.4M	Buy	250,924 +231,924	+1,221%	+$12.9M	0.74%	43
2015 Q4	$1.14M	Buy	19,000 +3,000	+19%	+$173K	0.06%	185
2015 Q3	$829K	Sell	16,000 -308,300	-95%	-$20.1M	0.04%	185
2015 Q2	$21.7M	Hold	324,300	–	–	1.12%	18
2015 Q1	$19M	Buy	324,300 +181,757	+128%	+$11M	0.91%	27
2014 Q4	$9.47M	Buy	142,543 +132,543	+1,325%	+$8.36M	0.43%	82
2014 Q3	$579K	Buy	10,000 +4,000	+67%	+$222K	0.03%	186
2014 Q2	$340K	Sell	6,000 -141,154	-96%	-$7.41M	0.01%	202
2014 Q1	$7.51M	Buy	147,154 +57,641	+64%	+$2.91M	0.56%	65
2013 Q4	$4.72M	Sell	89,513 -3,086	-3%	-$152K	0.28%	115
2013 Q3	$4.13M	Buy	+92,599	New	+$4.1M	0.29%	100

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Meag Munich Ergo's ABBV Position: Q2 2025 in Review

Meag Munich Ergo reduced its AbbVie (ABBV) stake by 7.8% in Q2 2025, selling an estimated $2.55M and leaving 162,557 shares worth $30.2M. The position accounts for 0.85% of the portfolio, ranked #48.

Meag Munich Ergo first reported a position in ABBV in Q3 2013 and has held it in 48 quarters since. The position peaked at $36.9M in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Meag Munich Ergo held 162,557 shares of AbbVie worth $30.2M as of Q2 2025.
Meag Munich Ergo sold 13,715 AbbVie shares in Q2 2025, an estimated $2.55M.
AbbVie made up 0.85% of Meag Munich Ergo's portfolio in Q2 2025, its #48 holding.
Meag Munich Ergo first reported a position in AbbVie in Q3 2013 and has held it in 48 quarters since.
Meag Munich Ergo's AbbVie position peaked at $36.9M in Q1 2025.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.